# Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

> **NCT04197219** · PHASE2 · WITHDRAWN · sponsor: **Case Comprehensive Cancer Center**

## Conditions studied

- Recurrent Endometrial Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT04197219
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI is leaving institution
- **Last updated:** 2020-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04197219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04197219, "Pembrolizumab With Axitinib in Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04197219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*